MedTrace Logo

The BeLimumab Antiphospholipid Syndrome Trial (BLAST)

NCT05020782 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-01-13

No results posted yet for this study

Summary

AIM: The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent aPL positivity and clinical features attributable to aPL that are resistant to warfarin and/or heparin.

Conditions

  • Antiphospholipid Syndrome

Interventions

DRUG

Belimumab

INTERVENTION DRUG: BELIMUMAB 10 MG/KG

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-10-01
Completion
2025-01-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020782 on ClinicalTrials.gov